Evolva Sa

Electrophoretics Limited

International Flavors & Fragrances Inc.

Joseph M Sheridan

Jonathan R Heal

William D O Hamilton

Ian Hugo Pike

Esben Halkjaer Hansen

Joergen Hansen

Honey Polur

William Do Hamilton

Jorgen Hansen

Veronique Douchin

Karsten Kuhn

Kim Olsson

Michael Naesby

Stefan Kienle

Laura Tatjer Recorda

Christian Nyffengger

Patricia Hoyle

Polur Honey

William DO Hamilton

Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.

Compositions and methods for the biosynthesis of vanillin or vanillin beta-d-glucoside

The present invention provides 2-Methyl-amino-3-[(4-fluorophenyl)carbonyl]indolizine-1-carboxamide of formula (I) or a pharmaceutically acceptable salt thereof; and its therapeutic uses in the treatment of neurodegenerative disorders, in particular tauopathies and most preferably in the treatment of Alzheimer's disease.

Casein kinase 1 delta inhibitor

The invention relates to recombinant microorganisms and methods for producing steviol glycosides, glycosides of steviol precursors, and steviol glycoside precursors.

Production of steviol glycosides in recombinant hosts

Compositions and methods for the biosynthesis of vanillan or vanillin beta-D-glucoside

The present disclosure provides methods for identifying anthocyanins with improved stability, color, or hue using a screening method, and producing anthocyanins with improved stability, color, or hue in, for example, host cells comprising one or more heterologous glycosyltransferase nucleic acid molecules and one or more heterologous acyltransferase nucleic acid molecules.

Anthocyanins with specific properties

The invention relates to pharmaceutical compositions having casein kinase 1 delta (CK1&#x3b4;) inhibitors and to the use of the inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.

Casein kinase 1&#x3b4; (CK 1&#x3b4;) inhibitors

Casein kinase 1delta (CK1delta) inhibitors

Growing community of inventors

Royston, United Kingdom

Joseph M Sheridan